CR10244A - Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano - Google Patents

Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano

Info

Publication number
CR10244A
CR10244A CR10244A CR10244A CR10244A CR 10244 A CR10244 A CR 10244A CR 10244 A CR10244 A CR 10244A CR 10244 A CR10244 A CR 10244A CR 10244 A CR10244 A CR 10244A
Authority
CR
Costa Rica
Prior art keywords
growth factor
antibody against
epitelial
human type
tumor therapy
Prior art date
Application number
CR10244A
Other languages
English (en)
Inventor
Friess Thomas
Hasmann Max
Scheuer Werner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37998279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10244(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR10244A publication Critical patent/CR10244A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un método par el tratamiento de la enfermedad de cáncer de mama en un paciente en el que previamente ha fallado un tratamiento con un anticuerpo anti-VEGF, que comprende la adminsitración al paciente de una cantidad terapéuticamente efectiva de un antincuerpo anti-HER2 mientras se continúa dicha terapia con anticuerpo anti-VEGF. La invención también proporciona los correspondientes antículos de elaboración y las composiciones farmacéuticas.
CR10244A 2006-03-22 2008-08-26 Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano CR10244A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06111523 2006-03-22
EP06021815 2006-10-18

Publications (1)

Publication Number Publication Date
CR10244A true CR10244A (es) 2008-10-29

Family

ID=37998279

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10244A CR10244A (es) 2006-03-22 2008-08-26 Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano

Country Status (25)

Country Link
US (4) US20070224203A1 (es)
EP (2) EP1998805B1 (es)
JP (2) JP5795463B2 (es)
KR (1) KR101089070B1 (es)
AR (1) AR059982A1 (es)
BR (1) BRPI0709025A2 (es)
CA (1) CA2645891A1 (es)
CR (1) CR10244A (es)
DK (2) DK1998805T3 (es)
EC (1) ECSP088753A (es)
ES (2) ES2392873T3 (es)
HK (1) HK1131037A1 (es)
HU (1) HUE029615T2 (es)
IL (1) IL193675A0 (es)
MA (1) MA30290B1 (es)
MX (1) MX2008012014A (es)
MY (1) MY151449A (es)
NO (1) NO20083761L (es)
NZ (1) NZ570921A (es)
PL (2) PL1998805T3 (es)
RU (1) RU2538664C2 (es)
SG (1) SG170730A1 (es)
SI (2) SI1998805T1 (es)
TW (1) TW200812615A (es)
WO (1) WO2007107329A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CA2407556C (en) * 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
KR20120068807A (ko) * 2004-07-22 2012-06-27 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
BRPI0518104B8 (pt) 2005-01-21 2021-05-25 Genentech Inc artigo industrializado e uso de anticorpo her2
UA95902C2 (ru) 2005-02-23 2011-09-26 Дженентек, Инк. Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MX2009001715A (es) * 2006-08-21 2009-02-25 Hoffmann La Roche Terapia tumoral con un anticuerpo anti-vegf.
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2012169822A2 (ko) * 2011-06-10 2012-12-13 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
EP4234033A3 (en) 2011-10-14 2023-09-20 F. Hoffmann-La Roche AG Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
PE20150361A1 (es) 2012-07-13 2015-03-14 Roche Glycart Ag Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
AU2014243783B2 (en) 2013-03-13 2018-12-13 Genentech, Inc. Antibody formulations
EP2986643A2 (en) 2013-04-16 2016-02-24 F. Hoffmann-La Roche AG Pertuzumab variants and evaluation thereof
MX2016014007A (es) 2014-04-25 2017-01-11 Genentech Inc Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab.
WO2016044334A1 (en) 2014-09-15 2016-03-24 Genentech, Inc. Antibody formulations
PT3302551T (pt) 2015-05-30 2024-08-21 H Hoffnabb La Roche Ag Métodos de tratamento do cancro da mama metastático positivo para her2 não tratado previamente
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
CN110099926A (zh) 2016-12-28 2019-08-06 豪夫迈·罗氏有限公司 晚期her2表达性癌症的治疗
SI3570884T1 (sl) 2017-01-17 2021-02-26 Genentech, Inc. Subkutane formulacije protiteles HER2
KR102417583B1 (ko) 2017-03-02 2022-07-07 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
JPH11512750A (ja) 1996-06-27 1999-11-02 ファイザー インク． ２―（２―オキソ―エチリデン）―イミダゾリジン―４―オンの誘導体およびファルネシル蛋白質トランスフェラーゼ阻害物質としてのそれらの使用法
KR100628846B1 (ko) 1996-10-18 2006-09-29 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DK1695985T3 (da) 1997-04-07 2011-06-14 Genentech Inc Fremgangsmåde til dannelse af humaniserede antistoffer ved tilfældig mutagenese
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DK0973804T3 (da) 1997-04-07 2007-05-07 Genentech Inc Anti-VEGF-antistoffer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
WO1999060023A1 (en) 1998-05-15 1999-11-25 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
OA11645A (en) 1998-08-27 2004-11-16 Pfizer Prod Inc Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents.
DE69923849T2 (de) 1998-08-27 2006-01-12 Pfizer Products Inc., Groton Quinolin-2-on-derivate verwendbar als antikrebsmittel
WO2000029584A1 (en) 1998-11-18 2000-05-25 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
EP2016953A3 (en) * 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
CN1340051A (zh) 1999-02-11 2002-03-13 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉－2－酮衍生物
CA2361877A1 (en) 1999-03-01 2000-09-08 Genentech, Inc. Antibodies for cancer therapy and diagnosis
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
SI1187632T1 (sl) 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU784045B2 (en) 1999-06-25 2006-01-19 Genentech Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DE60033658T2 (de) 1999-06-25 2007-11-22 Genentech, Inc., South San Francisco Behandlung von prostata-krebs mit anti-erbb2 antikörpern
AU778588B2 (en) * 1999-10-19 2004-12-09 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
DE60008206T2 (de) 1999-11-30 2004-12-02 Pfizer Products Inc., Groton Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
WO2003077841A2 (en) 2002-03-12 2003-09-25 The General Hospital Corporation Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
AU2003224916B2 (en) 2002-04-10 2009-01-08 Genentech, Inc. Anti-HER2 antibody variants
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
US20040243207A1 (en) 2003-05-30 2004-12-02 Olson Donald R. Medical implant systems
CA2534055A1 (en) 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
AU2004309347B2 (en) 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2

Also Published As

Publication number Publication date
EP2364732B1 (en) 2016-07-06
US20170239353A1 (en) 2017-08-24
DK2364732T3 (en) 2016-10-10
NO20083761L (no) 2008-10-09
KR20080096598A (ko) 2008-10-30
RU2538664C2 (ru) 2015-01-10
SI2364732T1 (sl) 2016-12-30
EP2364732A1 (en) 2011-09-14
AR059982A1 (es) 2008-05-14
MY151449A (en) 2014-05-30
US9090700B2 (en) 2015-07-28
RU2008141433A (ru) 2010-04-27
JP5795463B2 (ja) 2015-10-14
MX2008012014A (es) 2008-10-01
ES2595238T3 (es) 2016-12-28
ECSP088753A (es) 2008-10-31
KR101089070B1 (ko) 2011-12-05
TW200812615A (en) 2008-03-16
US20110064736A1 (en) 2011-03-17
MA30290B1 (fr) 2009-03-02
BRPI0709025A2 (pt) 2011-06-21
WO2007107329A1 (en) 2007-09-27
EP1998805B1 (en) 2012-08-22
DK1998805T3 (da) 2012-10-08
JP2012207036A (ja) 2012-10-25
HK1131037A1 (en) 2010-01-15
IL193675A0 (en) 2011-08-01
PL2364732T3 (pl) 2017-01-31
AU2007229008A1 (en) 2007-09-27
US20070224203A1 (en) 2007-09-27
ES2392873T3 (es) 2012-12-14
EP1998805A1 (en) 2008-12-10
SI1998805T1 (sl) 2012-12-31
PL1998805T3 (pl) 2013-01-31
HUE029615T2 (en) 2017-03-28
JP2009530333A (ja) 2009-08-27
SG170730A1 (en) 2011-05-30
NZ570921A (en) 2011-09-30
US20150283238A1 (en) 2015-10-08
CA2645891A1 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
CR10244A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
AR109246A2 (es) USO DE UN INMUNOCONJUGADO QUE COMPRENDE UN ANTICUERPO ANTI-ErbB2 PARA LA MANUFACTURA DE UN MEDICAMENTO
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
DOP2017000177A (es) Nuevos anticuerpos anti-cd38 para el tratamiento del cáncer
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
AR062840A1 (es) Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2)
CO6150193A2 (es) Terapia tumoral con anticuerpo anti-vegf
MX2021014094A (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso.
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
MX2022002592A (es) Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo.
JP2013543498A5 (es)
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
AR079256A1 (es) Metodo para el tratamiento del cancer de mama metastasico con trastuzumab-mcc-dm1
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
PE20160994A1 (es) Compuestos al receptor-3 del factor de crecimiento del fibroblasto (fgfr3) y metodos de tratamiento
AU2012253610A8 (en) Compositions and methods for treating cancer
PH12020551715A1 (en) Methods of treating cancer
CL2023000099A1 (es) Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
CL2018000726A1 (es) Tratamiento con conjugado syd985 de pacientes con cáncer resistente al tratamiento con t-dm1
UA95797C2 (ru) Терапия опухолей с использованием сосудистого эндотелиального фактора роста и антитела к рецептору типа 2 человеческого эпителиального фактора роста
Ghani Severe neutropenia and stomatitis: case report

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)